This is common in lymphomas where oncogenes are juxtaposed to the promoters of the immunoglobulin genes10, and also in prostate cancer where ETS TF (ERG) is fused with TMPRSS2 regulatory sequences, thus obtaining androgen receptor (AR)-responsive expression11. The gene discussed is AR; the disease is lymphoma.